CDC NEWS


powered by Surfing Waves


Latest News


Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine


21 Jan 2021

On December 11, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine, administered as 2 doses separated by 21 days.


Why a pioneering plan to distribute COVID vaccines equitably must succeed


13 Jan 2021

COVAX is key to both immunizing the world’s poorest people and ending the pandemic.


Science advisers: publish evidence behind COVID vaccine dosing strategy


12 Jan 2021

Countries that change established coronavirus vaccine schedules must be transparent, both to maintain public trust and so others can benefit from their knowledge.


Beyond Politics — Promoting Covid-19 Vaccination in the United States


06 Jan 2021

The United States has invested more than $10 billion in Operation Warp Speed to fast-track SARS-CoV-2 vaccines from conception to market in 1 year. The result is 11 candidates reaching the final stage of Food and Drug Administration testing — a phenomenal improvement over past development timelines. Indeed, two SARS-CoV-2 vaccines are already available to Americans.


What To Expect Of The COVID-19 Pandemic In 2021: Ask Our Experts


05 Jan 2021

Join our medical expert and wellness editor for a conversation about vaccines, when schools and businesses may reopen, and if life will return to normal.




Articles


We are scheduling training with them this week on how to generate the report.


07 Jun 2021

The Centers for Disease Control and Prevention (CDC) recently issued guidance that fully vaccinated individuals can safely remove masks and end social distancing in most indoor settings.1 Educational facilities and businesses are faced with whether and how to differentiate between vaccinated and unvaccinated individuals, including requiring proof of vaccination. Mandatory vaccination has historically served as a tool to reach and sustain high immunization coverage and to prevent transmission in K-12 schools, colleges/universities, and health care facilities. Vaccine mandates could extend to workers and customers in businesses to ensure safer environments. This Viewpoint examines the epidemiologic, public health, and legal considerations for mandatory SARS-CoV-2 vaccinations in each setting.




Mix-and-match COVID vaccines trigger potent immune response


19 May 2021

Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines.




Even Partial COVID-19 Vaccination Protects Nursing Home Residents


17 May 2021

A CDC analysis has shown that a single dose of the Pfizer-BioNTech COVID-19 vaccine protected medically vulnerable nursing home residents as well as it did general adult populations that were evaluated in other efficacy and effectiveness studies.




Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine


12 May 2021

The Moderna COVID-19 vaccine may cause a delayed localized hypersensitivity reaction with a median latency to onset of 7 days after vaccine administration. This pruritic and variably tender reaction has a median duration of 5 days, but may persist for up to 21 days, and may occur again and sooner after the second vaccine dose; no serious adverse events were observed in association with this cutaneous reaction to the Moderna COVID-19 vaccine.




The epidemiological impact of the NHS COVID-19 App


12 May 2021

The COVID-19 pandemic has seen digital contact tracing emerge around the world to help prevent spread of the disease. A mobile phone app records proximity events between app users, and when a user tests positive for COVID-19, their recent contacts can be notified instantly. Theoretical evidence has supported this new public health intervention1-6, but its epidemiological impact has remained uncertain7. Here we investigated the impact of the NHS COVID-19 app for England and Wales, from its launch on 24 September 2020 through to the end of December 2020. It was used regularly by approximately 16.5 million users (28% of the total population), and sent approximately 1.7 million exposure notifications: 4.4 per index case consenting to contact tracing. We estimated that the fraction of app-notified individuals subsequently showing symptoms and testing positive (the secondary attack rate, SAR) was 6.0%, comparable to the SAR for manually traced close contacts. We estimated the number of cases averted by the app using two complementary approaches. Modelling based on the notifications and SAR gave 284,000 (108,000-450,000), and statistical comparison of matched neighbouring local authorities gave 594,000 (317,000-914,000). Roughly one case was averted for each case consenting to notification of their contacts. We estimated that for every percentage point increase in app users, the number of cases can be reduced by 0.8% (modelling) or 2.3% (statistical analysis). These findings provide evidence for continued development and deployment of such apps in populations that are awaiting full protection from vaccines.




Enroll for Free